Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 45, Issue 2


HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive

Dorte A. Olsen / Birthe Østergaard / Susanne Bokmand / Peter A. Wamberg / Erik H. Jakobsen / Ivan Brandslund
  • Department of Clinical Biochemistry, Vejle County Hospital, Vejle, Denmark and The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2007-02-20 | DOI: https://doi.org/10.1515/CCLM.2007.034


Background: The level of HER-2/neu in breast cancer cells is normally measured by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). It determines whether patients should be treated with trastuzumab (Herceptin®). In this study, HER-2 protein in breast cancer tissue was measured using a quantitative method.

Methods: Tissue samples of malignant and adjacent benign breast tissue were collected from 118 consecutive women admitted for surgical treatment of breast cancer. The HER-2 protein concentration was determined by 2 HER-2 assays: ELISA and the Bayer ADVIA Centaur assay. Paraffin-embedded tissue sections of the corresponding tumors were analyzed by IHC and FISH.

Results: Increased HER-2 concentrations in cancer tissue were found compared to autologous reference tissue (p<0.0001, Wilcoxon test) and normal breast tissue (p<0.0001, Mann-Whitney test). Good concordance rates were observed between the methods: 95.8% for IHC and FISH; 86.4% for IHC and ELISA; and 87.3% for FISH and ELISA. The HER-2 positivity rate was determined to 26.3% by ELISA, 12.7% by IHC and 16.9% by FISH. No correlation was found with tumor grade, axillary node status or serum HER-2 levels.

Conclusions: Detection of HER-2 overexpression by measuring HER-2 in tissue extracts by ELISA seems to be more sensitive than IHC and FISH. This suggests that some patients deprived of Herceptin treatment may benefit from this treatment and may also explain the conversion phenomenon from HER-2-negative to HER-2-positive observed in relapse and metastatic disease.

Clin Chem Lab Med 2007;45:177–82.

Keywords: breast cancer; ELISA; ErbB2; fluorescence in situ hybridization; HER-2; immunohistochemistry

About the article

Corresponding author: Dorte A. Olsen, Department of Clinical Biochemistry, Vejle County Hospital, 7100 Vejle, Denmark Phone: +45-79406633, Fax: +45-79406871,

Received: September 12, 2006

Accepted: November 8, 2006

Published Online: 2007-02-20

Published in Print: 2007-02-01

Citation Information: Clinical Chemical Laboratory Medicine, Volume 45, Issue 2, Pages 177–182, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2007.034.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Oncology Reports, 2013, Volume 29, Number 4, Page 1475
Ana M. Gonzalez-Angulo and Gabriel N. Hortobagyi
Journal of Clinical Oncology, 2008, Volume 26, Number 10, Page 1585
Alicia L. Carlson, Ann M. Gillenwater, Michelle D. Williams, Adel K. El-Naggar, and R. R. Richards-Kortum
Technology in Cancer Research & Treatment, 2007, Volume 6, Number 5, Page 361
Bente Bull-Hansen, Yu Cao, Kristian Berg, Ellen Skarpen, Michael G. Rosenblum, and Anette Weyergang
Journal of Controlled Release, 2014, Volume 182, Page 58
Patricia Diana Sørensen, Erik Hugger Jakobsen, Jonna Skov Madsen, Eva Brix Petersen, Rikke Fredslund Andersen, Birthe Østergaard, and Ivan Brandslund
Journal of Cancer Research and Clinical Oncology, 2013, Volume 139, Number 6, Page 1005
Else Maae, Dorte Aalund Olsen, Karina Dahl Steffensen, Erik Hugger Jakobsen, Ivan Brandslund, Flemming Brandt Sørensen, and Anders Jakobsen
Breast Cancer Research and Treatment, 2012, Volume 133, Number 1, Page 257
D. M. Collins, N O'Donovan, P. M. McGowan, F. O'Sullivan, M. J. Duffy, and J. Crown
Annals of Oncology, 2012, Volume 23, Number 7, Page 1788
Hakan Mersin, Emin Yildirim, Ugur Berberoglu, and Kaptan Gülben
The Breast, 2008, Volume 17, Number 4, Page 341
Jens-Jacob L. Lauterlein, Eva R.B. Petersen, Dorte Aa. Olsen, Birthe Østergaard, and Ivan Brandslund
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 5
Dorte Aa. Olsen, Birthe Østergaard, Susanne Bokmand, Peter A. Wamberg, Erik H. Jakobsen, Anders Jakobsen, and Ivan Brandslund
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 8
Patricia Diana Sørensen, Erik Hugger Jakobsen, Sven Tyge Langkjer, Susanne Bokmand, Birthe Østergaard, Dorte Aalund Olsen, Jonna Skov Madsen, and Ivan Brandslund
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 9
Maksym Yezhelyev, Rami Yacoub, and Ruth O’Regan
Nanomedicine, 2009, Volume 4, Number 1, Page 83

Comments (0)

Please log in or register to comment.
Log in